Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Big Pharma counsel embrace AI but data and legal risks loom
Americas
Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.   24 October 2024
10x Genomics counsel: ‘Winning cases is a top priority’
Americas
10x Genomics senior director of IP and litigation shares her team's tasks, how she’s handling UPC litigation, and why sometimes she wants a ‘gut answer’ from externals, finds Marisa Woutersen.   22 October 2024
HR, lobbying and business strategy…all in a day’s work for today’s counsel
Americas
In-house pharma and biotech lawyers are taking on broader roles, from handling regulatory issues to corporate strategy—and outside counsel can help, finds Marisa Woutersen.   22 October 2024
Americas
At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.   17 October 2024
Americas
As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.   17 October 2024
Europe
Duo successfully invalidate two CureVac patents in the UK | High Court deems patents invalid due to lack of inventive step and insufficient technical contribution | CureVac “disappointed” but stressed outcome does not affect ongoing litigation in Germany and US.   10 October 2024
Europe
Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen.   9 October 2024
Europe
A UK court upholds the patent for Astellas Pharma's life-extending prostate cancer treatment | Judgment dismisses attempts by Accord Healthcare, Sandoz, and Teva to invalidate the patent | Parallel litigation in Germany and Netherlands ongoing.   8 October 2024
Unified Patent Court
Having been involved in more than 30 cases at the UPC, the Bardehle Pagenberg litigator tells Marisa Woutersen why success at the game-changing court is a team effort.   1 October 2024
Europe
Jennifer Godorn Wessman is leading efforts to protect the medtech company’s key assets. She sat down with LSIPR to discuss her team’s challenges, expanding into new markets, and why lawyers are salespeople too.   26 September 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.